Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Patients With Cardiovascular Disease on Stable Lipid-Lowering Therapy Requiring Additional LDL-C Reduction
Latest Information Update: 30 May 2024
At a glance
- Drugs Lerodalcibep (Primary) ; Bempedoic acid; Bezafibrate; Bile acids and salts; Ezetimibe; Fenofibrate; HMG-CoA reductase inhibitors; Nicotinic acids; Omega-3-fatty-acid
- Indications Hypercholesterolaemia
- Focus Registrational; Therapeutic Use
- Acronyms LIBerate-005; LIBerate-CVD
- Sponsors LIB Therapeutics
- 29 May 2024 According to a LIB Therapeutics media release, Primary endpoint (mean LDL-C change at week 50 and 52) has been met.
- 29 May 2024 According to a LIB Therapeutics media release, Primary endpoint (LDL-C change compared to placebo) has been met.
- 29 May 2024 According to a LIB Therapeutics media release, data from the study were presented at the 92nd European Atherosclerosis Society Congress in Lyon, France, May 26-29, 2024.